ClinicalTrials.gg
CompletedNCT00097942Updated Mar 5, 2012

Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients

A Phase 2 interventional study of memantine HCl in Schizophrenia, sponsored by Forest Laboratories. Completed at 13 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-03-05.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing memantine in Schizophrenia — none open to participants now, none under way, none of them phase 3. Memantine · Schizophrenia.

Enrollment
2nd of 11
138 · median 42
Started
2004
with 1 other
Phase 2
2 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
1 of 11
Forest Laboratories

Among the 11 studies testing memantine in Schizophrenia, this one is the 2nd largest by enrollment, is one of 2 that started in 2004, is one of 2 in phase 2, and was the 1st registered.

Schizophrenia

3,567 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 11 studies testing memantine in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

Where they have run

About memantine

Memantine: first FDA approval 2003 (NAMENDA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing memantine in Schizophrenia as a file.
02

Study summary

Standard antipsychotic drug regimens do not fully address the impact of cognitive symptoms associated with schizophrenia. The NMDA receptor has been connected to the pathophysiology of schizophrenia. Memantine is an uncompetitive NMDA receptor antagonist. It is hypothesized that adjunctive therapy with memantine will reduce NMDA receptor hyperactivity, improving signal to noise ratio and thereby improving cognitive symptoms.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • memantine
  • adjunctive therapy
  • schizophrenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed Schizophrenia or schizoaffective disorder who are on a stable antipsychotic regimen with Brief Psychiatric Rating Scale (BPRS) total score greater than or equal to 26 and greater than or equal to 4 on at least one item

Exclusion criteria

Exclusion Criteria:

  • Secondary diagnosis of Bipolar I disorder
  • Suicidal history
  • Organic brain disease
  • Dementia
  • History of substance abuse
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
138 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Positive and Negative Symptom Scale (PANSS) - Total Score

Secondary outcomes

  1. Clinical Global Impression - Severity (CGI-S)

  2. PANNS - Positive Score

  3. PANSS - Negative Score

  4. Calgary Depression Scale for Schizophrenia

  5. Brief Assessment of Cognition

  6. Clinical Global Impression - Improvement

07

Study locations

13 sites
  • Synergy Clinical Research
    National City, California 91950, United States
  • VA San Diego Healthcare System
    San Diego, California 92161, United States
  • University of Miami Jackson Memorial Hospital
    Miami, Florida 33136, United States
  • University of Iowa Psychiatric Research
    Iowa City, Iowa 52242, United States
  • CBH Health, LLC
    Rockville, Maryland 20850, United States
  • Metropolitan Psychiatric Center
    St. Louis, Missouri 63112, United States
  • Dartmouth Hitchcock Medical School
    Lebanon, New Hampshire 03755, United States
  • Nathan Kline Institute
    Orangeburg, New York 10962, United States
  • Duke University John Umstead Hospital
    Butner, North Carolina 27509, United States
  • UNC - Chapel Hill, Clinical Research Unit
    Raleigh, North Carolina 27699-3601, United States
  • University of Cincinnati Medical Science Building
    Cincinnati, Ohio 45267-0559, United States
  • University Hills Clinical Research
    Irving, Texas 75062, United States
  • Medication Research Clinic
    San Antonio, Texas 78207, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2004, a primary completion of Sep 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2004
First posted
Dec 2, 2004
Start
Aug 2004
Primary completionActual
Sep 2005
CompletionActual
Sep 2005
Last update
Mar 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00097942
First posted
Dec 2, 2004
Start date
Aug 2004
Primary completion
Sep 2005
Completion
Sep 2005
Last update
Mar 5, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Memantine

Start the discussion